Diabetic dyslipidaemia and residual risk in the era of LDL control
Video navigation menu
Addressing residual risk by lowering LDL in diabetic dyslipidaemia may not be enough 0:09
Insulin resistance affects lipid metabolism in diabetic patients 3:04
Are other lipid parameters better than LDL-c to identify residual risk in statin-treated patients? 5:29
Triglyceride-rich lipoproteins may be an important target 6:53
Data on triglyceride-lowering agents in outcome trials 8:41
Evaluating the CV effect of a PPAR agonist in T2DM patients in the planned PROMINENT trial 10:03
The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.
Share this page with your colleagues and friends: